Home » Stocks » Immunic

Immunic, Inc. (IMUX)

Stock Price: $20.34 USD 1.64 (8.77%)
Updated Aug 10, 2020 11:40 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 406.16M
Revenue (ttm) n/a
Net Income (ttm) -39.11M
Shares Out 14.97M
EPS (ttm) -3.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $20.34
Previous Close $18.70
Change ($) 1.64
Change (%) 8.77%
Day's Open 19.05
Day's Range 18.71 - 20.50
Day's Volume 436,521
52-Week Range 4.19 - 23.39

More Stats

Market Cap 406.16M
Enterprise Value 388.05M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 14.97M
Float 10.79M
EPS (basic) -3.69
EPS (diluted) -3.28
FCF / Share -3.34
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 132,808
Short Ratio 0.38
Short % of Float 1.84%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.43
Revenue n/a
Operating Income -41.38M
Net Income -39.11M
Free Cash Flow -35.86M
Net Cash 18.11M
Net Cash / Share 0.91
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -36.86%
ROE -48.42%
ROIC 2,808.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$60.00*
(194.99% upside)
Low
57.0
Current: $20.34
High
64.0
Target: 60.00
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue--------
Operating Income-37.03-12.00-52.66-41.27-52.12-50.34-31.40-9.58
Net Income-34.93-11.54-52.08-40.97-52.02-47.67-32.72-6.70
Shares Outstanding7.720.851.000.780.630.400.010.01
Earnings Per Share-4.52-13.63-52.40-52.40-82.80-141.60-2,994.40-715.60
Operating Cash Flow-28.55-9.74-40.40-35.77-49.95-40.83-28.65-9.24
Capital Expenditures-0.02-0.03-0.68-0.55-2.34-1.41-1.48-0.24
Free Cash Flow-28.56-9.77-41.08-36.33-52.29-42.23-30.13-9.49
Cash & Equivalents29.3713.0756.9059.9983.9510439.1518.83
Total Debt0.52-------
Net Cash / Debt28.8513.0756.9059.9983.9510439.1518.83
Assets65.9613.3760.3864.0389.0810846.5920.33
Liabilities7.591.9210.345.586.7610.5291.2427.96
Book Value58.36-25.7450.0458.4582.3397.56-44.66-7.63
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Immunic, Inc.
Country United States
Employees 26
CEO Daniel Vitt

Stock Information

Ticker Symbol IMUX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IMUX

Description

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis. The company is also developing IMU-935, an inverse agonist of RORyt; and IMU-856 for the restoration of the intestinal barrier function. Immunic, Inc. is headquartered in San Diego, California.